In a FEP sample, we measured multiple immune markers at baseline, reflecting activity in immunoinflammatory pathways that a) are assumed to be altered in a state-independent manner in psychotic disorders [12], and b) have previously been linked to treatment resistance, illness severity, and/or positive symptoms across different psychotic disorders in cross-sectional studies (CRP: e.g., [22–24, 57–59]; IL-1RA: e.g., [25, 60, 61]; sTNFR1: e.g., [26, 60, 62, 63]; sIL-2R: e.g., [28, 64, 65]; IL-6 pathway: e.g., [23, 24, 27, 59, 66]). The gene discussed is CRP; the disease is psychotic disorder.